Bispecific Antibody Meets Antibody-Drug Conjugate in Promising Small Cell Lung Cancer Trial
First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...
First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...
A new Perspective argues that next-generation oncolytic viruses act as antigen-agnostic in situ vaccines capable of priming de novo antitumor ...
Pancreatic cancer is notoriously resistant to immunotherapy because many tumors develop an immune-suppressive, oxygen-poor “cold” microenvironment that blocks effective T ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine